Long-term effects of dalfampridine in patients with multiple sclerosis

Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment par...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the neurological sciences Jg. 337; H. 1-2; S. 18 - 24
Hauptverfasser:	Ruck, T., Bittner, S., Simon, O.J., Göbel, K., Wiendl, H., Schilling, M., Meuth, S.G.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Netherlands Elsevier B.V 15.02.2014
Schlagworte:	4-Aminopyridine - therapeutic use Cognition Disorders - drug therapy Cognition Disorders - etiology Dalfampridine Disability Evaluation Drug Delivery Systems Electroencephalography Evoked Potentials - drug effects Evoked Potentials - physiology Fatigue Female Follow-Up Studies Humans Long-term treatment Male Middle Aged Mobility Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neurology Potassium Channel Blockers - therapeutic use Severity of Illness Index Statistics, Nonparametric Time Factors Walking - physiology Walking ability Mobility Fatigue Dalfampridine Long-term treatment MS Walking ability
ISSN:	0022-510X, 1878-5883, 1878-5883
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!